Drug class
Sodium-Glucose Transporter 2 Inhibitors clinical trials
A class of medicines: the studies that test any of its 16 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the sodium-glucose transporter 2 inhibitors studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
- Luseogliflozin
- 2
- Rongliflozin l-pyroglutamic acid
- 2
- Rongliflozin
- 1
- AVE2268
- 1
Studies by the year they started
1,273 studies that test it; most in 2022 (112); 3 more planned to start later
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 3 |
| 2006 | 9 |
| 2007 | 21 |
| 2008 | 29 |
| 2009 | 34 |
| 2010 | 63 |
| 2011 | 47 |
| 2012 | 18 |
| 2013 | 24 |
| 2014 | 47 |
| 2015 | 61 |
| 2016 | 73 |
| 2017 | 85 |
| 2018 | 57 |
| 2019 | 57 |
| 2020 | 67 |
| 2021 | 84 |
| 2022 | 112 |
| 2023 | 99 |
| 2024 | 109 |
| 2025 | 98 |
| 2026 | 75 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 544 · Other 732
AstraZeneca (108) · Boehringer Ingelheim (93) · Astellas Pharma Inc (38) · Janssen Research & Development, LLC (37) · Lexicon Pharmaceuticals (34) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (28) · Daewoong Pharmaceutical Co. LTD. (26) · Merck Sharp & Dohme LLC (22)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 1,276
- Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin ResistanceNot yet recruitingPhase 4Sherihan AboElyazed Mohamed KhalilNCT07891234Written as Dapagliflozin 5Mg Tab
- Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE PreventionRecruitingPhase 3Insel Gruppe AG, University Hospital BernNCT06653738Written as Empagliflozin 10 MG
- Canagliflozin Plus Progestin for Atypical Endometrial Hyperplasia and Early-Stage Endometrial CancerNot yet recruitingPhase 2Wang YingmeiNCT07890064Written as Canagliflozin
- Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis PatientsRecruitingPhase 2Chinese University of Hong KongNCT06483074Written as Empagliflozin 10 MG
- Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With ObesityRecruitingPhase 2VA Office of Research and DevelopmentNCT06745063Written as Empagliflozin
- Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinRecruitingPhase 3AstraZenecaNCT06677060Written as Baxdrostat and dapagliflozin
- dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized EvaluationNot yet recruitingPhase 2University Medical Center GroningenNCT06072326Written as Dapagliflozin (Forxiga®)
- EMBRACE (EMPA in BReast Cancer for Activity and Cardiac ProtEction)Not yet recruitingPhase 2Virginia Commonwealth UniversityNCT07883512Written as Empagliflozin
- Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart FailureRecruitingEarly Phase 1University of MinnesotaNCT06507657Written as empagliflozin
- Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult PatientsRecruitingPhase 3University Hospital GoettingenNCT05944016Written as Dapagliflozin
- Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 FibrosisRecruitingPhase 4Madrigal Pharmaceuticals, Inc.NCT07848191Written as FARXIGA/dapagliflozin
- Feasibility Trial for a Right Ventricular Failure Platform TrialRecruitingPhase 2University of AlbertaNCT06570473Written as Empagliflozin
- A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the BodyRecruitingPhase 1Boehringer IngelheimNCT07845630Written as Empagliflozin
- Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMIRecruitingNot applicableMohammad Hussien Tantawy SolimanNCT06009874Written as Dapagliflozin 10mg Tab
- Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)Enrolling by invitationPhase 4Baylor Research InstituteNCT07547878Written as Invokana
- STunning in Acute Myocardial Infarction - BASRecruitingPhase 4Vastra Gotaland RegionNCT06562582Written as Dapagliflozin Oral Product
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Empagliflozin
- Evaluation of Dapagliflozin and Empagliflozin as Adjunctive Therapy to Methotrexate in Patients With Rheumatoid ArthritisNot yet recruitingPhase 2Al-Azhar UniversityNCT07864688Written as Dapagliflozin
- Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's DiseaseNot yet recruitingPhase 2Wake Forest University Health SciencesNCT07756294Written as Empagliflozin
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureRecruitingPhase 3AstraZenecaNCT06742723Written as Baxdrostat/dapagliflozin
See all 1,276 studies that test one of the sodium-glucose transporter 2 inhibitors →
Codes
What other systems call Sodium-Glucose Transporter 2 Inhibitors · ClinicalTrials.gg INT006659
- MeSH (NLM) D000077203Sodium-Glucose Transporter 2 InhibitorsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077203 | Sodium-Glucose Transporter 2 Inhibitors | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.